ArticleJournal of pain research2024
Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of the Science, Knowledge Gaps, and Imperatives for Clinical Adoption.
Article in Journal of pain research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 13 citations in OpenAlex.
- Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study.BMC musculoskeletal disorders · 2025Trial
- Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain: Evaluation of Clinical Outcomes and Quality of Life in Medicare Beneficiaries.Clinical interventions in aging · 2025Trial
- Biomaterials for intervertebral disc regeneration: Niche reprogramming, precision therapeutics, and structural reconstruction.Bioactive materials · 2027Review
- Article
- Comparing Medicare Claims in Patients with Lumbar Discogenic Pain Managed Conservatively or with Intradiscal Nucleus Pulposus Allograft.Journal of pain research · 2026Article
- Safety Evaluation of Intradiscal Delivery of Nucleus Pulposus Allograft for Lumbar Discogenic Pain.International journal of spine surgery · 2025Article
- Clinical Efficacy and Risks of Intradiscal Orthobiological Injections: A Narrative Review.Current pain and headache reports · 2025Review
- Pathomechanics of Early-Stage Lumbar Intervertebral Disc Degradation Leading to Discogenic Pain-A Narrative Review.Bioengineering (Basel, Switzerland) · 2025Review
- Biologic Therapies for Discogenic Pain.Current pain and headache reports · 2025Review
- A Proposed Diagnostic and Treatment Algorithm for the Management of Lumbar Discogenic Pain.Journal of pain research · 2025Article
- A Primer on Anatomy, Biophysics, Pathology, Imaging and Treatment of the Intervertebral Disc and the Anterior Spinal Column: The Discogenic, Intervertebral, Spinal Column (DISC) ASPN Workgroup.Journal of pain research · 2025Article
- Durability of Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain.Journal of pain research · 2025Article
- Delayed percutaneous intradiscal hydrogel herniation causing neurological injury after minor trauma: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Current Therapeutic Strategies of Intervertebral Disc Regenerative Medicine.Molecular diagnosis & therapy · 2024Review
- Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process.Pharmaceutics · 2024Article
- The Role of ISASS in Evolving the Spine Code Landscape: Lumbar Discogenic Pain Receives Specific ICD-10-CM Code.International journal of spine surgery · 2024Article
- A Self-Polymerizing Mesh of Nano-Tethers for the Mechanical Constraint of Degraded Intervertebral Discs-A Review of 25 Years of Pre-Clinical and Early Clinical Research.Bioengineering (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specific clinical diagnostic criteria have established a consensus for defining patients with lumbar discogenic pain. However, if conservative medical management fails, these patients have few treatment options short of surgery involving discectomy often coupled with fusion or arthroplasty. There is a rapidly-emerging research effort to fill this treatment gap with intradiscal therapies that can be delivered minimally-invasively via fluoroscopically guided injection without altering the normal anatomy of the affected vertebral motion segment. Viable candidate products to date have included mesenchymal stromal cells, platelet-rich plasma, nucleus pulposus structural allograft, and other cell-based compositions. The objective of these products is to repair, supplement, and restore the damaged intervertebral disc as well as retard further degeneration. In doing so, the intervention is meant to eliminate the source of discogenic pain and avoid surgery. Methodologically rigorous studies are rare, however, and based on the best clinical evidence, the safety as well as the magnitude and duration of clinical efficacy remain difficult to estimate. Further, we summarize the US Food and Drug Administration's (FDA) guidance regarding the interpretation of the minimal manipulation and homologous use criteria, which is central to designating these products as a tissue or as a drug/device/biologic. We also provide perspectives on the core evidence and knowledge gaps associated with intradiscal therapies, propose imperatives for evaluating effectiveness of these treatments and highlight several new technologies on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.